R A Carr1, A M Roch1, K Shaffer1, S Aboudi1, C M Schmidt3, J DeWitt2, E P Ceppa1, M G House1, N J Zyromski1, A Nakeeb1, C M Schmidt3. 1. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Department of Medicine, Division of Gastroenterology, Indiana University Hospital, Indianapolis, IN, USA. 3. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: maxschmi@iupui.edu.
Abstract
BACKGROUND: Patients with intraductal papillary mucinous neoplasm (IPMN) are at risk for invasive pancreatic cancer. We aim to characterize the impact of smoking on IPMN malignant progression. METHODS: Patients undergoing pancreatic resection for IPMN (1991-2015) were retrospectively reviewed using a prospectively collected database. RESULTS: Of 422 patients identified, 324 had complete data for analysis; 55% were smokers. Smoking status did not impact IPMN malignant progression (smokers/non-smokers: 22%/18% invasive grade; p = 0.5). Smokers were younger than non-smokers at the time of IPMN diagnosis (63 versus 68 years; p = 0.001). This association also held in the invasive IPMN subgroup (65 versus 72 years, p = 0.01). Despite this observation, rate of symptoms at diagnosis, cancer stage, and median survival were the same between smokers and non-smokers. CONCLUSION: Although smoking is not associated with IPMN malignant progression, invasive IPMN is diagnosed at a younger age in smokers. These data suggest tobacco exposure may accelerate IPMN malignant progression.
BACKGROUND:Patients with intraductal papillary mucinous neoplasm (IPMN) are at risk for invasive pancreatic cancer. We aim to characterize the impact of smoking on IPMN malignant progression. METHODS:Patients undergoing pancreatic resection for IPMN (1991-2015) were retrospectively reviewed using a prospectively collected database. RESULTS: Of 422 patients identified, 324 had complete data for analysis; 55% were smokers. Smoking status did not impact IPMN malignant progression (smokers/non-smokers: 22%/18% invasive grade; p = 0.5). Smokers were younger than non-smokers at the time of IPMN diagnosis (63 versus 68 years; p = 0.001). This association also held in the invasive IPMN subgroup (65 versus 72 years, p = 0.01). Despite this observation, rate of symptoms at diagnosis, cancer stage, and median survival were the same between smokers and non-smokers. CONCLUSION: Although smoking is not associated with IPMN malignant progression, invasive IPMN is diagnosed at a younger age in smokers. These data suggest tobacco exposure may accelerate IPMN malignant progression.
Authors: Vicente Morales-Oyarvide; Mari Mino-Kenudson; Cristina R Ferrone; Andrew L Warshaw; Keith D Lillemoe; Dushyant V Sahani; Ilaria Pergolini; Marc A Attiyeh; Mohammad Al Efishat; Neda Rezaee; Ralph H Hruban; Jin He; Matthew J Weiss; Peter J Allen; Christopher L Wolfgang; Carlos Fernández-Del Castillo Journal: J Gastrointest Surg Date: 2017-10-18 Impact factor: 3.452
Authors: Kasper A Overbeek; Maaike Alblas; Valerie Gausman; Pujan Kandel; Adam B Schweber; Christian Brooks; Priscilla A Van Riet; Michael B Wallace; Tamas A Gonda; Djuna L Cahen; Marco J Bruno Journal: Aliment Pharmacol Ther Date: 2019-08-19 Impact factor: 8.171